Elevidys Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to lack of curative dmd treatments, historical reliance on supportive care, early gene therapy research, rare disease drug incentives, initial regulatory approvals.

The growth in the forecast period can be attributed to advancements in gene editing platforms, increasing investment in neuromuscular research, growing newborn screening initiatives, expansion of specialty treatment centers, favorable regulatory pathways. Major trends in the forecast period include growth of gene therapy adoption, rising focus on curative treatments, expansion of dmd targeted therapies, increasing early intervention strategies, advancements in viral vector delivery.

The rising burden of Duchenne muscular dystrophy (DMD) is expected to drive growth in the elevidys market. Duchenne muscular dystrophy is a genetic disorder caused by mutations in the dystrophin gene, which prevent the production of dystrophin, a critical muscle protein, leading to progressive muscle weakness and degeneration. The increasing burden of DMD is largely due to growing awareness and improved diagnostic capabilities, which enable earlier and more frequent identification of the condition. Elevidys treats DMD by delivering a micro-dystrophin gene to muscle cells, partially restoring dystrophin protein function. For example, in December 2023, Murdoch Children’s Research Institute, an Australia-based child health research center, reported that approximately 1,000 individuals in Australia are affected by DMD. Consequently, the rising prevalence of Duchenne muscular dystrophy is expected to propel the elevidys market.

A key trend in the elevidys market is the development of innovative drug solutions, such as gene therapy, to support early diagnosis and personalized treatment plans for patients with Duchenne muscular dystrophy. Gene therapy for DMD involves delivering a functional copy of the dystrophin gene or a microdystrophin variant into muscle cells to address the underlying genetic cause of the disease. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based company specializing in medical research and drug development, received FDA approval for Elevidys (delandistrogene moxeparvovec-rokl), marking it as the first gene therapy for Duchenne muscular dystrophy. The approval covers ambulatory pediatric patients aged 4 to 5 years with a confirmed DMD gene mutation.

In January 2023, Sarepta Therapeutics partnered with Catalent to enhance the development and manufacturing of gene therapies for Duchenne muscular dystrophy. The collaboration focuses on producing delandistrogene moxeparvovec (SRP-9001), Sarepta’s gene therapy candidate for DMD, which delivers a gene encoding a shortened form of dystrophin to muscle cells. Catalent Inc. is a US-based provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.

Major companies operating in the elevidys market are Sarepta Therapeutics Inc.

North America was the largest region in the elevidys market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elevidys market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the elevidys market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the elevidys market by increasing costs related to viral vectors, gene delivery materials, and advanced manufacturing equipment. These impacts are most visible in specialty hospital and research institution segments, particularly in regions dependent on imported gene therapy components. Elevated tariffs can influence pricing strategies and slow adoption in emerging markets. However, tariffs are also encouraging domestic production capabilities, technology transfer initiatives, and long term infrastructure development for gene therapy manufacturing.

The elevidys market research report is one of a series of new reports that provides elevidys market statistics, including elevidys industry global market size, regional shares, competitors with a elevidys market share, detailed elevidys market segments, market trends and opportunities, and any further data you may need to thrive in the elevidys industry. This elevidys market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Elevidys is a prescription gene therapy developed by Sarepta Therapeutics for Duchenne muscular dystrophy (DMD), targeting the underlying cause of the disease. It delivers a shortened yet functional version of the dystrophin gene (micro-dystrophin) to enhance muscle strength and function.

The primary indications for elevidys include Duchenne muscular dystrophy and related conditions. DMD is a genetic disorder characterized by the progressive weakening and loss of muscle tissue due to the absence of dystrophin, an essential muscle protein. Elevidys works by introducing a gene that produces micro-dystrophin, a smaller form of dystrophin, to protect muscle cells and slow disease progression. It is distributed through specialty pharmacies, hospitals, and clinics, and is used by end users including research institutions and homecare settings.

The elevidys market consists of sales of elevidys suspension. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.